Lisa Bouchet, Zachary Sager, Antoine Yrondi, Kabir B Nigam, Brian T Anderson, Stephen Ross, Petros D Petridis, Yvan Beaussant
BACKGROUND: Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety, existential distress, and posttraumatic stress disorder. AIMS: The goal of this study was to quantify the prevalence of older adults enrolled in psychedelic clinical trials and explore safety data in this population...
January 2024: Journal of Psychopharmacology